Efficacy and safety of cannabinoid oromucosal spray for multiple sclerosis spasticity

BackgroundThe approval of 9-δ-tetrahydocannabinol and cannabidiol (THC:CBD) oromucosal spray (Sativex) for the management of treatment-resistant multiple sclerosis (MS) spasticity opened a new opportunity for many patients. The aim of our study was to describe Sativex effectiveness and adverse event...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Journal of neurology, neurosurgery and psychiatry Jg. 87; H. 9; S. 944 - 951
Hauptverfasser:	Patti, F, Messina, S, Solaro, C, Amato, M P, Bergamaschi, R, Bonavita, S, Bruno Bossio, R, Brescia Morra, V, Costantino, G F, Cavalla, P, Centonze, D, Comi, G, Cottone, S, Danni, M, Francia, A, Gajofatto, A, Gasperini, C, Ghezzi, A, Iudice, A, Lus, G, Maniscalco, G T, Marrosu, M G, Matta, M, Mirabella, M, Montanari, E, Pozzilli, C, Rovaris, M, Sessa, E, Spitaleri, D, Trojano, M, Valentino, P, Zappia, M
Format:	Journal Article
Sprache:	Englisch
Veröffentlicht:	England BMJ Publishing Group LTD 01.09.2016 BMJ Publishing Group
Schriftenreihe:	Research paper
Schlagworte:	Administration, Oral Cannabidiol Clinical trials Data collection Dronabinol Drug Combinations Drugs Humans Italy Multiple Sclerosis Multiple Sclerosis - complications Multiple Sclerosis - drug therapy Muscle Spasticity - drug therapy Muscle Spasticity - etiology Normal distribution Observational studies Patients Plant Extracts - administration & dosage Plant Extracts - therapeutic use Safety Software Spasticity Variables Italy
ISSN:	0022-3050, 1468-330X, 1468-330X
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!